These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. Blake SJ; Ching AL; Kenna TJ; Galea R; Large J; Yagita H; Steptoe RJ PLoS One; 2015; 10(3):e0119483. PubMed ID: 25741704 [TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261 [TBL] [Abstract][Full Text] [Related]
13. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
14. Diacylglycerol kinase zeta negatively regulates CXCR4-stimulated T lymphocyte firm arrest to ICAM-1 under shear flow. Lee D; Kim J; Beste MT; Koretzky GA; Hammer DA Integr Biol (Camb); 2012 Jun; 4(6):606-14. PubMed ID: 22546945 [TBL] [Abstract][Full Text] [Related]
15. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048 [TBL] [Abstract][Full Text] [Related]
16. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. Wesley EM; Xin G; McAllister D; Malarkannan S; Newman DK; Dwinell MB; Cui W; Johnson BD; Riese MJ Immunohorizons; 2018 Apr; 2(4):107-118. PubMed ID: 30027154 [TBL] [Abstract][Full Text] [Related]
17. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272 [TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980 [TBL] [Abstract][Full Text] [Related]
19. Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis. Zhou J; Peng H; Li K; Qu K; Wang B; Wu Y; Ye L; Dong Z; Wei H; Sun R; Tian Z Immunity; 2019 Feb; 50(2):403-417.e4. PubMed ID: 30709740 [TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Šmahel M Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]